Relevant or Relegated? Radiotherapy for Stage III NSCLC in the Neoadjuvant Era

There are many ongoing advances in the multidisciplinary management of stage III NSCLC, in particular the advent of neoadjuvant immunotherapy in patients who are resectable. This paradigm shift has resulted in a retooling of different treatment pathways for patients, failure to stay informed on current developments and controversies in this space leads to lower quality of care by practicing clinicians.

Stage III NSCLC represents one of the most heterogenous subgroups of lung cancer, wherein there are several multimodality treatment options. These are most often informed in the context of operability and resectability. In the present molecular era, biomarkers also have strong implications in the choice of systemic therapy, as well as prognosis. In practice, the choice and sequence of multimodality treatment varies substantially among clinicians, across institutions, and even within an institution. This multidisciplinary educational activity, led by representatives from thoracic surgery, radiation oncology and medical oncology, reviews the current state of the art evaluation, workup and treatment options in stage III NSCLC. Particular emphasis is placed on the emergence of neoadjuvant immunotherapy-based treatment prior to surgery, and its implication on the role of radiotherapy in the neoadjuvant, definitive and adjuvant scenarios. Finally, practical considerations for future directions and current controversies are reviewed and discussed.

Topics:

  1. The Med Onc Perspective - Biomarkers and Precision Systemic Therapy
    Stephen V. Liu, MD
  2. Operability and Resectability in Stage III NSCLC - A Surgeon's Perspective
    Erin A. Gillaspie, MD
  3. Practical Radiotherapy Considerations for Stage III NSCLC in the Neoadjuvant Immunotherapy Era
    Houda Bahig, MD, PhD
  4. Radiotherapy Renaissance - What's Next in Stage III NSCLC?
    Alexander V. Louie, MD, PhD, MSc, FRCPC
  5. Q and A
    Full Panel

This activity is available from December 17, 2024, through 11:59 p.m. Eastern time on December 16, 2026. 

This activity was originally recorded at the 2024 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, dosimetrists, radiation biologists, residents and pulmonologists.   

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize the relevant roles of biomarker testing, novel therapeutics and precision surgery/radiotherapy in the management of stage III NSCLC.
  • Recognize the difference in the meaning of resectability and operability, as it relates to stage III NSCLC.
  • Review the continued role of radiotherapy in the curative management of stage III NSCLC, including neoadjuvant/adjuvant and definitive strategies. 
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.
Course opens: 
12/17/2024
Course expires: 
12/16/2026
Cost:
$0.00
Rating: 
0
  • Alexander V. Louie, MD, PhD, MSc, FRCPC, is employed by Sunnybrook Health Sciences Centre, University of Toronto. Dr. Louie receives honoraria from AstraZeneca.
  • Stephen V. Liu, MD, is employed by Lombardi Comprehensive Cancer Center, Georgetown University. Dr. Liu serves as a consultant for Abbvie, AstraZeneca, Boehringer Ingelheim, BMS, Candel Therapeutics, Catalyst, Daiichi Sankyo, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz Pharmaceuticals, Merck, Merus, Mirati, Novartis, OSE Immunotherapeutics, Pfizer, RAPT, Regeneron, Revolution Medicines, Sanofi, Takeda and Yuhan. 
  • Erin A. Gillaspie, MD, is employed by Creighton University. Dr. Gillaspie receives honoraria for consulting work from AstraZeneca, Genentech, BMS and Intuitive Surgical. 
  • Houda Bahig, MD, PhD, is employed by Centre Hospitalier de l'Universite de Montreal. Dr. Bahig receives grant/research funding from AstraZeneca and Varian Medical Systems. Dr. Bahig receives honoraria and compensation/payment from AstraZeneca, Serono and Need, Inc. 

The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.

Disclosure link: 
Committee Disclosures

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification. 

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

Nonmember: $149
Member: $99
Member-in-training: $49
Student/Grad Student/PGY: $49
Postdoctoral Fellow: $49

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.

Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.

The course and its materials will only be available on the ASTRO website until December 16, 2026, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.